2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
83
Neoplasm Metastasis
10
Neoplasms
6
Prostatic Neoplasms, Castration-Resistant
5
Carcinoma, Non-Small-Cell Lung
4
Metastatic Castration-Resistant Prostate Cancer
3
Colorectal Neoplasms
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Castration-resistant Prostate Cancer
2
Carcinoma, Hepatocellular
2
Bulbo-Spinal Atrophy, X-Linked
2
Breast Neoplasms
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Solid Tumours
1
Salivary Gland Neoplasms
1
Interventions
Cisplatin
7
Etoposide
6
pembrolizumab
4
Topotecan
4
Pemetrexed
4
Carboplatin
4
Gemcitabine
3
belinostat
2
Temozolomide
2
RRx-001
2
Paclitaxel
2
vosaroxin
1
vinflunine
1
veliparib
1
taxane
1
sagopilone
1
sacituzumab govitecan
1
pomalidomide
1
lurtotecan
1
liposomal doxorubicin
1
etoposide phosphate
1
enzalutamide
1
bemiparin
1
belotecan
1
atezolizumab
1
apalutamide
1
alvocidib
1
abiraterone
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
abiraterone
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts